Mahato Ranjit Kumar, Singh Mohini, Pathak Hemanta, Gogoi Niva Rani, Kharbithai Rikynjai, Chowrasia Pinky, Bora Pankaj Lochan, Sarkar Tumpa, Jana Bani Kumar, Mazumder Bhaskar
Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, 786004, Assam, India.
Ther Deliv. 2023 Sep;14(9):543-569. doi: 10.4155/tde-2023-0033. Epub 2023 Sep 6.
Atopic dermatitis is a prevalent chronic skin inflammation affecting 2.1 to 4.1% of adults globally. The complexity of its pathogenesis and the relapsing nature make it challenging to treat. Current treatments follow European Academy of Dermatology and Venerology guidelines, but advanced cases with recurring lesions lack effective therapies. To address this gap, researchers are exploring nanotechnology for targeted drug delivery. Nanoparticles offer benefits such as improved drug retention, stability, controlled release and targeted delivery through the disrupted epidermal barrier. This integrated review evaluates the current state of AD treatment and highlights the potential of novel nano-formulations as a promising approach to address the disease.
特应性皮炎是一种常见的慢性皮肤炎症，全球2.1%至4.1%的成年人受其影响。其发病机制的复杂性和复发性使其治疗具有挑战性。目前的治疗遵循欧洲皮肤病与性病学会的指南，但对于复发性皮损的晚期病例缺乏有效的治疗方法。为了填补这一空白，研究人员正在探索纳米技术用于靶向药物递送。纳米颗粒具有诸多优势，如通过破坏的表皮屏障改善药物滞留、稳定性、控释和靶向递送。这篇综合综述评估了特应性皮炎治疗的现状，并强调了新型纳米制剂作为治疗该疾病的一种有前景方法的潜力。
